- Home
- PMA vs CTXR Comparison
PMA vs CTXR Comparison
Compare PMA & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMA | CTXR |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 18.9M |
| IPO Year | 2024 | 2010 |
Fundamental Metrics
Financial Performance| Metric | PMA | CTXR |
|---|---|---|
| Price | $1.25 | $0.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 98.6K | ★ 419.8K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $0.47 |
| 52 Week High | $1.53 | $2.19 |
Technical Indicators
Market Signals| Indicator | PMA | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 55.66 |
| Support Level | N/A | $0.55 |
| Resistance Level | $1.33 | $0.61 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 41.34 | 61.08 |
Price Performance
Historical ComparisonAbout CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.